Dublin, Nov. 27, 2025 (GLOBE NEWSWIRE) -- The "Pipeline of CD40 Agonists and CD40/L Antagonists" report has been added to ResearchAndMarkets.com's offering. This competitive intelligence report about ...

The semaglutide market offers major opportunities in expanding obesity treatments and oral formulations, capitalizing on ...

Rachael Link is a registered dietitian and health writer based in San Francisco. She completed her undergraduate degree at the University of Central Missouri and holds a master’s degree from New York ...

Novo Nordisk (NYSE:NVO) A/S, a global healthcare company specializing in diabetes care and other chronic conditions, has been at the forefront of the rapidly expanding GLP-1 market. With a market ...

(MENAFN- GlobeNewsWire - Nasdaq) The main market opportunities lie in developing CD40-targeting therapies, including agonists for cancer immunotherapy and antagonists for autoimmune diseases.